The table below shows Amneal Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$722.52M
$784.51M
$724.51M
$695.42M
$702.47M
$701.78M
Cost of revenue
$402.41M
$510.54M
$438.25M
$439.53M
$432.91M
$451.83M
Gross profit
$320.11M
$273.97M
$286.25M
$255.89M
$269.56M
$249.95M
R&D
$38.38M
$63.35M
$47.96M
$40.04M
$61.10M
$36.05M
AMRX annual revenue (10-K history)
Amneal Pharmaceuticals, Inc. reported annual revenue of $3.02B for fiscal year 2025. That is up 8.0% from $2.79B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.02B (FY 2016) to $3.02B. Figures come from the company's audited annual reports as filed with the SEC.
